Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24399939 | 0.63 | APP (0.46) | — | |
| SCHEMBL22462840 | 0.62 | KCNH2 (0.44) | — | |
| SCHEMBL31071609 | 0.60 | HTR2C (0.35) | ALDH2 | |
| SCHEMBL31071582 | 0.60 | CHRNB2 (0.41) | — | |
| SCHEMBL31379713 | 0.59 | GRM5 (0.46) | — | |
| SCHEMBL31071559 | 0.57 | HTR2C (0.39) | — | |
| SCHEMBL31071580 | 0.56 | OPRM1 (0.36) | — | |
| SCHEMBL31071568 | 0.53 | CHRNB2 (0.39) | — | |
| SCHEMBL22462945 | 0.53 | CHRNB2 (0.39) | — | |
| SCHEMBL22531091 | 0.52 | HTR2C (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194596-A1 | Therapeutic Combination Including a Selective Erbb2 Inhibitor | FRIZER INC. | 2008-08-14 | — | — | US | disclosed |
| US-20050101618-A1 | Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer | PFIZER INC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101618-A1 | Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer | ERBB2, ERBB3, EGFR | ALDH2 4447/4885 |
| US-20080194596-A1 | Therapeutic Combination Including a Selective Erbb2 Inhibitor | ERBB2, ERBB3, EGFR | ALDH2 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.